Materiały źródłowe

• #1 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Many people with CML do not have symptoms when diagnosed. The most common sign of CML is an abnormal white blood cell count often found during blood tests for an unrelated health problem or during a routine checkup. To diagnose CML, doctors use a variety of tests to analyze blood and bone marrow cells. A pathologist, a doctor who specializes in identifying diseases by studying cells under a microscope, will examine the blood cells and the bone marrow cells. The samples should also be examined by a hematopathologist, a specialist who diagnoses diseases of the blood and marrow. […] […] Complete Blood Count (CBC) with Differential. This test is used to measure the number red blood cells, white blood cells and platelets in a sample of blood. It also measures the amount of hemoglobin in the red blood cells and the percentage of red blood cells in the sample. The CBC should include a differential. The differential measures the different types of white blood cells in the sample.

• #2 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  Many people with chronic myeloid leukemia (CML) don’t have symptoms when it’s diagnosed. […] The leukemia is often found when their doctor orders blood tests for an unrelated health problem or during a routine check-up. […] If signs and symptoms suggest you may have leukemia, the doctor will need to check your blood and bone marrow to be certain of this diagnosis. […] These samples are sent to a lab, where they’re checked under a microscope for leukemia cells. […] Most people with CML have too many white blood cells with a lot of early (immature) cells called myeloblasts or blasts. […] An important factor is whether the cells look mature (like normal circulating blood cells) or immature (lacking features of normal circulating blood cells). […] Sometimes CML patients have low numbers of red blood cells or blood platelets.

• #3 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Many people with CML do not have symptoms when diagnosed. The most common sign of CML is an abnormal white blood cell count often found during blood tests for an unrelated health problem or during a routine checkup. To diagnose CML, doctors use a variety of tests to analyze blood and bone marrow cells. A pathologist, a doctor who specializes in identifying diseases by studying cells under a microscope, will examine the blood cells and the bone marrow cells. The samples should also be examined by a hematopathologist, a specialist who diagnoses diseases of the blood and marrow. […] […] Complete Blood Count (CBC) with Differential. This test is used to measure the number red blood cells, white blood cells and platelets in a sample of blood. It also measures the amount of hemoglobin in the red blood cells and the percentage of red blood cells in the sample. The CBC should include a differential. The differential measures the different types of white blood cells in the sample.

• #4 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Many people with CML do not have symptoms when diagnosed. The most common sign of CML is an abnormal white blood cell count often found during blood tests for an unrelated health problem or during a routine checkup. To diagnose CML, doctors use a variety of tests to analyze blood and bone marrow cells. A pathologist, a doctor who specializes in identifying diseases by studying cells under a microscope, will examine the blood cells and the bone marrow cells. The samples should also be examined by a hematopathologist, a specialist who diagnoses diseases of the blood and marrow. […] […] Complete Blood Count (CBC) with Differential. This test is used to measure the number red blood cells, white blood cells and platelets in a sample of blood. It also measures the amount of hemoglobin in the red blood cells and the percentage of red blood cells in the sample. The CBC should include a differential. The differential measures the different types of white blood cells in the sample.

• #5 Diagnostic criteria for chronic myeloid leukemia

  https://www.medicalnewstoday.com/articles/chronic-myeloid-leukemia-diagnostic-criteria

  Chronic myeloid leukemia (CML) is a type of blood cancer that people may also refer to as chronic myelogenous leukemia. Doctors diagnose the stage of CML based on the number of leukemia cells, or blast cells, present in the blood. […] Healthcare professionals can confirm a diagnosis of CML using the results of a complete blood count (CBC) test. This test measures the number of red blood cells, platelets, and white blood cells present in a sample of a persons blood. […] The CBC should also include a differential, which measures the different types of white blood cells. […] A person with CML will have increased levels of a type of white blood cell called granulocytes, along with an increase in immature white blood cells. […] Following the CBC, healthcare professionals may perform genetic tests to look for the BCR-ABL gene, which is a fusion gene, and a type of genetic mutation known as the Philadelphia chromosome.

• #6 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  People with CML often have: An increased white blood cell count, often a very high level; A decreased red blood cell count; A possible increase or decrease in the number of platelets, depending on the severity of the disease. […] […] Bone Marrow Aspiration and Biopsy. These tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patients hip bone after medicine has been given to numb the skin. For a bone marrow aspiration, a hollow needle is inserted through the hip bone and into the bone marrow to remove a liquid sample of cells. For a bone marrow biopsy, a wider needle is used to remove a small piece of bone that contains marrow. Both samples are examined under a microscope to look for chromosomal and other cell changes. […]

• #7 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  Many people with chronic myeloid leukemia (CML) don’t have symptoms when it’s diagnosed. […] The leukemia is often found when their doctor orders blood tests for an unrelated health problem or during a routine check-up. […] If signs and symptoms suggest you may have leukemia, the doctor will need to check your blood and bone marrow to be certain of this diagnosis. […] These samples are sent to a lab, where they’re checked under a microscope for leukemia cells. […] Most people with CML have too many white blood cells with a lot of early (immature) cells called myeloblasts or blasts. […] An important factor is whether the cells look mature (like normal circulating blood cells) or immature (lacking features of normal circulating blood cells). […] Sometimes CML patients have low numbers of red blood cells or blood platelets.

• #8 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  People with CML often have: An increased white blood cell count, often a very high level; A decreased red blood cell count; A possible increase or decrease in the number of platelets, depending on the severity of the disease. […] […] Bone Marrow Aspiration and Biopsy. These tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patients hip bone after medicine has been given to numb the skin. For a bone marrow aspiration, a hollow needle is inserted through the hip bone and into the bone marrow to remove a liquid sample of cells. For a bone marrow biopsy, a wider needle is used to remove a small piece of bone that contains marrow. Both samples are examined under a microscope to look for chromosomal and other cell changes. […]

• #9 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  People with CML often have: An increased white blood cell count, often a very high level; A decreased red blood cell count; A possible increase or decrease in the number of platelets, depending on the severity of the disease. […] […] Bone Marrow Aspiration and Biopsy. These tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patients hip bone after medicine has been given to numb the skin. For a bone marrow aspiration, a hollow needle is inserted through the hip bone and into the bone marrow to remove a liquid sample of cells. For a bone marrow biopsy, a wider needle is used to remove a small piece of bone that contains marrow. Both samples are examined under a microscope to look for chromosomal and other cell changes. […]

• #10 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  Many people with chronic myeloid leukemia (CML) don’t have symptoms when it’s diagnosed. […] The leukemia is often found when their doctor orders blood tests for an unrelated health problem or during a routine check-up. […] If signs and symptoms suggest you may have leukemia, the doctor will need to check your blood and bone marrow to be certain of this diagnosis. […] These samples are sent to a lab, where they’re checked under a microscope for leukemia cells. […] Most people with CML have too many white blood cells with a lot of early (immature) cells called myeloblasts or blasts. […] An important factor is whether the cells look mature (like normal circulating blood cells) or immature (lacking features of normal circulating blood cells). […] Sometimes CML patients have low numbers of red blood cells or blood platelets.

• #11 Diagnostic criteria for chronic myeloid leukemia

  https://www.medicalnewstoday.com/articles/chronic-myeloid-leukemia-diagnostic-criteria

  Chronic myeloid leukemia (CML) is a type of blood cancer that people may also refer to as chronic myelogenous leukemia. Doctors diagnose the stage of CML based on the number of leukemia cells, or blast cells, present in the blood. […] Healthcare professionals can confirm a diagnosis of CML using the results of a complete blood count (CBC) test. This test measures the number of red blood cells, platelets, and white blood cells present in a sample of a persons blood. […] The CBC should also include a differential, which measures the different types of white blood cells. […] A person with CML will have increased levels of a type of white blood cell called granulocytes, along with an increase in immature white blood cells. […] Following the CBC, healthcare professionals may perform genetic tests to look for the BCR-ABL gene, which is a fusion gene, and a type of genetic mutation known as the Philadelphia chromosome.

• #12 Chronic Myeloid Leukemia (CML) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/chronic-myeloid-leukemia-cml

  Chronic myeloid leukemia (CML) occurs when a pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, leading to a striking overproduction of mature and immature granulocytes. […] Peripheral blood smear, bone marrow aspirate, and demonstration of the Philadelphia chromosome are diagnostic. […] Chronic myeloid leukemia is most frequently suspected based on an abnormal CBC obtained incidentally or during evaluation of splenomegaly. […] Diagnosis is confirmed by finding the Ph chromosome in samples examined with cytogenetic or molecular studies. […] The peripheral smear (typically showing immature granulocytes, basophilia, and eosinophilia) helps distinguish CML from leukocytosis of other etiologies (eg, leukocytosis due to infection). […] Tyrosine kinase inhibitors are extremely effective, prolong survival, and may even be curative. […] Stem cell transplantation can be curative and may help patients who do not respond to tyrosine kinase inhibitors or who progress to accelerated or blast phase.

• #13 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  Even though these findings may suggest leukemia, this diagnosis usually needs to be confirmed by another blood test or a test of the bone marrow. […] Checking the bone marrow for leukemia cells is a key part of testing for it. […] These bone marrow tests are used to help diagnose leukemia, but they might also be repeated later to tell if the leukemia is responding to treatment. […] In people with CML, the bone marrow is often hypercellular because it’s full of leukemia cells. […] Some sort of gene testing will be done to look for the Philadelphia chromosome and/or the BCR-ABL gene. […] This type of test is used to confirm a CML diagnosis and learn more about your CML cells. […] Finding a Ph chromosome is helpful in diagnosing CML. […] But even when the Ph chromosome can’t be seen, other tests can often find the BCR-ABL gene.

• #14 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  People with CML often have: An increased white blood cell count, often a very high level; A decreased red blood cell count; A possible increase or decrease in the number of platelets, depending on the severity of the disease. […] […] Bone Marrow Aspiration and Biopsy. These tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patients hip bone after medicine has been given to numb the skin. For a bone marrow aspiration, a hollow needle is inserted through the hip bone and into the bone marrow to remove a liquid sample of cells. For a bone marrow biopsy, a wider needle is used to remove a small piece of bone that contains marrow. Both samples are examined under a microscope to look for chromosomal and other cell changes. […]

• #15 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422

  A needle suctioning out liquid bone marrow from hipbone Bone marrow exam […] In a bone marrow aspiration, a healthcare professional uses a thin needle to remove a small amount of liquid bone marrow. It is usually taken from a spot in the back of the hip bone, also called the pelvis. A bone marrow biopsy is often done at the same time. This second procedure removes a small piece of bone tissue and the enclosed marrow. […] Tests and procedures used to diagnose chronic myelogenous leukemia include: […] Blood tests. A sample of blood is drawn using a needle. The sample is sent to a lab for a complete blood count, also called a CBC. A CBC checks the number of different types of cells in the blood. Chronic myelogenous leukemia often causes a very high number of white blood cells. Blood tests also can measure organ function to show if anything isn’t working properly.

• #16 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  People with CML often have: An increased white blood cell count, often a very high level; A decreased red blood cell count; A possible increase or decrease in the number of platelets, depending on the severity of the disease. […] […] Bone Marrow Aspiration and Biopsy. These tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patients hip bone after medicine has been given to numb the skin. For a bone marrow aspiration, a hollow needle is inserted through the hip bone and into the bone marrow to remove a liquid sample of cells. For a bone marrow biopsy, a wider needle is used to remove a small piece of bone that contains marrow. Both samples are examined under a microscope to look for chromosomal and other cell changes. […]

• #17 Chronic myeloid leukaemia diagnosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/diagnosis/

  If the results of your blood tests suggest that you might have CML, a bone marrow biopsy may be required to help confirm the diagnosis. A bone marrow biopsy involves taking a sample of bone marrow (usually from the back of the hip bone) and sending it to the laboratory for examination under the microscope. The bone marrow biopsy may be done in the haematologist’s rooms, clinic or day procedure centre and is usually performed under local anaesthesia with sedation given either by tablet or through a small drip in your arm. […] The sample of bone marrow is examined in the laboratory to determine the number and type of cells present and the amount of haemopoiesis (blood forming) activity taking place there. The diagnosis of CML is confirmed by the detection of the Philadelphia (Ph) chromosome or the bcr-abl gene in the bone marrow cells. Other findings may include a very active marrow filled with large numbers of mature and immature white cells and platelets.

• #18 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422

  Bone marrow tests. Bone marrow biopsy and bone marrow aspiration are used to collect bone marrow samples for testing. Bone marrow has a solid and a liquid part. In a bone marrow biopsy, a needle is used to collect a small amount of the solid tissue. In a bone marrow aspiration, a needle is used to draw a sample of the fluid. The samples are typically taken from the hip bone. The samples go to a lab for testing. […] Tests to look for the Philadelphia chromosome. Specialized tests are used to analyze blood or bone marrow samples for the presence of the Philadelphia chromosome or the BCR-ABL gene. These tests may include fluorescence in situ hybridization analysis, also called FISH, and polymerase chain reaction test, also called PCR. […] The phase of chronic myelogenous leukemia refers to the aggressiveness of the disease. Your health care provider determines the phase by measuring the ratio of diseased cells to healthy cells in your blood or bone marrow. A higher ratio of diseased cells means chronic myelogenous leukemia is at a more advanced stage.

• #19 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422

  Bone marrow tests. Bone marrow biopsy and bone marrow aspiration are used to collect bone marrow samples for testing. Bone marrow has a solid and a liquid part. In a bone marrow biopsy, a needle is used to collect a small amount of the solid tissue. In a bone marrow aspiration, a needle is used to draw a sample of the fluid. The samples are typically taken from the hip bone. The samples go to a lab for testing. […] Tests to look for the Philadelphia chromosome. Specialized tests are used to analyze blood or bone marrow samples for the presence of the Philadelphia chromosome or the BCR-ABL gene. These tests may include fluorescence in situ hybridization analysis, also called FISH, and polymerase chain reaction test, also called PCR. […] The phase of chronic myelogenous leukemia refers to the aggressiveness of the disease. Your health care provider determines the phase by measuring the ratio of diseased cells to healthy cells in your blood or bone marrow. A higher ratio of diseased cells means chronic myelogenous leukemia is at a more advanced stage.

• #20 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  Even though these findings may suggest leukemia, this diagnosis usually needs to be confirmed by another blood test or a test of the bone marrow. […] Checking the bone marrow for leukemia cells is a key part of testing for it. […] These bone marrow tests are used to help diagnose leukemia, but they might also be repeated later to tell if the leukemia is responding to treatment. […] In people with CML, the bone marrow is often hypercellular because it’s full of leukemia cells. […] Some sort of gene testing will be done to look for the Philadelphia chromosome and/or the BCR-ABL gene. […] This type of test is used to confirm a CML diagnosis and learn more about your CML cells. […] Finding a Ph chromosome is helpful in diagnosing CML. […] But even when the Ph chromosome can’t be seen, other tests can often find the BCR-ABL gene.

• #21 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  Even though these findings may suggest leukemia, this diagnosis usually needs to be confirmed by another blood test or a test of the bone marrow. […] Checking the bone marrow for leukemia cells is a key part of testing for it. […] These bone marrow tests are used to help diagnose leukemia, but they might also be repeated later to tell if the leukemia is responding to treatment. […] In people with CML, the bone marrow is often hypercellular because it’s full of leukemia cells. […] Some sort of gene testing will be done to look for the Philadelphia chromosome and/or the BCR-ABL gene. […] This type of test is used to confirm a CML diagnosis and learn more about your CML cells. […] Finding a Ph chromosome is helpful in diagnosing CML. […] But even when the Ph chromosome can’t be seen, other tests can often find the BCR-ABL gene.

• #22 Chronic myeloid leukaemia diagnosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/diagnosis/

  If the results of your blood tests suggest that you might have CML, a bone marrow biopsy may be required to help confirm the diagnosis. A bone marrow biopsy involves taking a sample of bone marrow (usually from the back of the hip bone) and sending it to the laboratory for examination under the microscope. The bone marrow biopsy may be done in the haematologist’s rooms, clinic or day procedure centre and is usually performed under local anaesthesia with sedation given either by tablet or through a small drip in your arm. […] The sample of bone marrow is examined in the laboratory to determine the number and type of cells present and the amount of haemopoiesis (blood forming) activity taking place there. The diagnosis of CML is confirmed by the detection of the Philadelphia (Ph) chromosome or the bcr-abl gene in the bone marrow cells. Other findings may include a very active marrow filled with large numbers of mature and immature white cells and platelets.

• #23 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Cytogenetic Analysis. Cytogenetics is the study of chromosomes and chromosomal abnormalities. In these tests, special stains are applied to a bone marrow sample and then the cells are examined for chromosomal changes or abnormalities, such as the Philadelphia (Ph) chromosome. The presence of the Ph chromosome in the bone marrow cells, along with a high white blood cell count and other characteristic blood and bone marrow test findings, confirm the diagnosis of CML. In about 95 percent of people with CML, the Ph chromosome in bone marrow cells is detectable by cytogenetic analysis. In a small percentage of people with clinical signs of CML, the Ph chromosome cannot be detected by cytogenetic analysis. However, these patients almost always test positive for the BCR::ABL1 fusion gene on chromosome 22, found with the other types of tests, such as FISH and qPCR. […]

• #24 Chronic myelogenous leukemia – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/symptoms-causes/syc-20352417

  Chronic myelogenous leukemia often doesn’t cause symptoms. It might be detected during a blood test. […] Most people with chronic myelogenous leukemia have a chromosome called the Philadelphia chromosome inside their blood cells. […] The Philadelphia chromosome is present in the blood cells of 90% of people with chronic myelogenous leukemia. […] The gene change that leads to chronic myelogenous leukemia isn’t passed from parents to children. This change is believed to develop after birth. […] Chronic myelogenous leukemia happens when something causes changes to the bone marrow cells. It’s not clear what starts this process. However, doctors have discovered how it progresses into chronic myelogenous leukemia. […] In chronic myelogenous leukemia, this process doesn’t work properly. The tyrosine kinase allows too many white blood cells to grow. Most or all of these cells contain the Philadelphia chromosome. The diseased white blood cells don’t grow and die like they should. The diseased white blood cells build up in huge numbers. They crowd out healthy blood cells and damage the bone marrow.

• #25 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Chronic myeloid leukemia (CML) is a malignancy characterized by the presence of the Philadelphia (Ph) chromosome. A presumptive diagnosis of CML is usually made by examining blood cell counts and peripheral smears, often during the chronic phase. Detection of BCR-ABL1 in the blood or bone marrow confirms the diagnosis. Laboratory methods used in the diagnosis, prognosis, and monitoring of CML include chromosome banding analysis (karyotyping), fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcription polymerase chain reaction (RT-PCR). […] The diagnosis of CML is confirmed by the presence of the Ph chromosome and/or BCR-ABL1 transcripts in blood or bone marrow by chromosome banding analysis, RT-PCR, or FISH. If neither the Ph chromosome nor BCR-ABL1 are detected, evaluation for other myeloproliferative neoplasms should be considered.

• #26 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Conventional bone marrow cytogenetics, specifically chromosome banding analysis (karyotyping) of at least 20 Giemsa-stained metaphases from the bone marrow, is recommended at diagnosis. Karyotyping is used for the detection of the Ph chromosome and can identify atypical (i.e., three way) translocations resulting in Ph chromosome formation. […] RT-PCR testing should be performed along with chromosomal karyotyping at initial diagnosis for baseline BCR-ABL1 transcript identification and quantification. A quantitative RT-PCR test for the relevant BCR-ABL1 transcript should be performed at the initial workup and for therapeutic response assessment and monitoring. […] FISH testing may be used if chromosome banding analysis cannot be performed or if the breakpoint is cryptic and cannot be detected by chromosome banding analysis. FISH tests can detect nearly all variant and cryptic Ph translocations and can confirm the diagnosis of CML if BCR and ABL1 probes are used.

• #27 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Cytogenetic Analysis. Cytogenetics is the study of chromosomes and chromosomal abnormalities. In these tests, special stains are applied to a bone marrow sample and then the cells are examined for chromosomal changes or abnormalities, such as the Philadelphia (Ph) chromosome. The presence of the Ph chromosome in the bone marrow cells, along with a high white blood cell count and other characteristic blood and bone marrow test findings, confirm the diagnosis of CML. In about 95 percent of people with CML, the Ph chromosome in bone marrow cells is detectable by cytogenetic analysis. In a small percentage of people with clinical signs of CML, the Ph chromosome cannot be detected by cytogenetic analysis. However, these patients almost always test positive for the BCR::ABL1 fusion gene on chromosome 22, found with the other types of tests, such as FISH and qPCR. […]

• #28 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Conventional bone marrow cytogenetics, specifically chromosome banding analysis (karyotyping) of at least 20 Giemsa-stained metaphases from the bone marrow, is recommended at diagnosis. Karyotyping is used for the detection of the Ph chromosome and can identify atypical (i.e., three way) translocations resulting in Ph chromosome formation. […] RT-PCR testing should be performed along with chromosomal karyotyping at initial diagnosis for baseline BCR-ABL1 transcript identification and quantification. A quantitative RT-PCR test for the relevant BCR-ABL1 transcript should be performed at the initial workup and for therapeutic response assessment and monitoring. […] FISH testing may be used if chromosome banding analysis cannot be performed or if the breakpoint is cryptic and cannot be detected by chromosome banding analysis. FISH tests can detect nearly all variant and cryptic Ph translocations and can confirm the diagnosis of CML if BCR and ABL1 probes are used.

• #29 European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia | Leukemia

  https://www.nature.com/articles/s41375-023-02048-y

  At presentation, up to 85-90% of CML cases have a t(9;22)(q34;q11) on cytogenetic analysis and thus have a standard Ph chromosome, sometimes described as 22q- or der22. […] A minimum of 20 metaphases should be analysed (ideally 25) to ensure detection of ACAs. […] Cytogenetic testing should include a screen for ACAs at diagnosis. […] BCR::ABL1 mRNA transcript type should be determined for all cases prior to treatment to enable appropriate follow up. […] The possibility of a rare BCR::ABL1 variant should be excluded. If testing for rare variants is not available, the diagnostic report should clearly state that the presence of a BCR::ABL1 remains a possibility and that further testing in an appropriate reference laboratory should be performed. […] Identification of atypical BCR::ABL1 variants may be challenging, and there are no CE-marked or Food and Drug Administration (FDA)-approved kits or systems that can detect most rare isoforms. […] For centres that use cytogenetics and/or FISH as the primary screen, the BCR::ABL1 transcript type in positive cases should be determined prior to starting treatment to facilitate accurate assessment of measurable residual disease (MRD) on therapy.

• #30 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Fluorescence In Situ Hybridization (FISH). This laboratory test is used to examine genes and chromosomes in cells. It is a slightly more sensitive method for detecting CML than the standard cytogenetic tests used to identify the Ph chromosome. FISH tests can identify the presence of the BCR::ABL1 gene. […] […] Quantitative Polymerase Chain Reaction (qPCR). The qPCR test is the most sensitive test used to detect and measure the quantity of the BCR::ABL1 gene in blood or bone marrow samples. It can detect very small amounts of the BCR::ABL1 gene, even when the Ph chromosome cannot be detected in blood or bone marrow cells with cytogenetic testing. It is capable of detecting one CML cell among 100,000 normal cells.

• #31 Chronic Myeloid Leukemia (CML): Diagnosis 

  https://healthlibrary.somc.org/Library/DiseasesConditions/Adult/Cardiovascular/34,BCMLD2

  Cytogenetics. For these tests, cells are grown in a lab for a week or more. The chromosomes inside the cells are then stained with special dyes and looked at with a microscope. Major problems in the chromosomes can often be seen. But smaller changes may not be visible. These tests often take a few weeks because the cells need time to be grown in the lab. […] Fluorescence in situ hybridization (FISH). This test is another way to look for changes in chromosomes. The cells in the sample are stained with fluorescent dyes that will attach only to certain parts of chromosomes. The cells are then viewed with a special light. This test can find some chromosome changes that can’t be seen with standard cytogenetic testing. It’s also a quicker test. […] Polymerase chain reaction (PCR). This is a very sensitive test that can detect very low levels of BCR-ABL in a test sample. It works by increasing the amount of genetic material in a sample so that it can be found. This test can find very small levels of the BCR-ABL gene that other tests may not find. […] Getting your test results Your healthcare provider will contact you with the results. Your provider will talk with you about other tests you may need if CML is found. Make sure you understand the results and what follow-up you need.

• #32 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Fluorescence In Situ Hybridization (FISH). This laboratory test is used to examine genes and chromosomes in cells. It is a slightly more sensitive method for detecting CML than the standard cytogenetic tests used to identify the Ph chromosome. FISH tests can identify the presence of the BCR::ABL1 gene. […] […] Quantitative Polymerase Chain Reaction (qPCR). The qPCR test is the most sensitive test used to detect and measure the quantity of the BCR::ABL1 gene in blood or bone marrow samples. It can detect very small amounts of the BCR::ABL1 gene, even when the Ph chromosome cannot be detected in blood or bone marrow cells with cytogenetic testing. It is capable of detecting one CML cell among 100,000 normal cells.

• #33 Chronic Myeloid Leukemia (CML): Diagnosis 

  https://healthlibrary.somc.org/Library/DiseasesConditions/Adult/Cardiovascular/34,BCMLD2

  Cytogenetics. For these tests, cells are grown in a lab for a week or more. The chromosomes inside the cells are then stained with special dyes and looked at with a microscope. Major problems in the chromosomes can often be seen. But smaller changes may not be visible. These tests often take a few weeks because the cells need time to be grown in the lab. […] Fluorescence in situ hybridization (FISH). This test is another way to look for changes in chromosomes. The cells in the sample are stained with fluorescent dyes that will attach only to certain parts of chromosomes. The cells are then viewed with a special light. This test can find some chromosome changes that can’t be seen with standard cytogenetic testing. It’s also a quicker test. […] Polymerase chain reaction (PCR). This is a very sensitive test that can detect very low levels of BCR-ABL in a test sample. It works by increasing the amount of genetic material in a sample so that it can be found. This test can find very small levels of the BCR-ABL gene that other tests may not find. […] Getting your test results Your healthcare provider will contact you with the results. Your provider will talk with you about other tests you may need if CML is found. Make sure you understand the results and what follow-up you need.

• #34 Chronic Myeloid Leukemia (CML): Diagnosis 

  https://healthlibrary.somc.org/Library/DiseasesConditions/Adult/Cardiovascular/34,BCMLD2

  Cytogenetics. For these tests, cells are grown in a lab for a week or more. The chromosomes inside the cells are then stained with special dyes and looked at with a microscope. Major problems in the chromosomes can often be seen. But smaller changes may not be visible. These tests often take a few weeks because the cells need time to be grown in the lab. […] Fluorescence in situ hybridization (FISH). This test is another way to look for changes in chromosomes. The cells in the sample are stained with fluorescent dyes that will attach only to certain parts of chromosomes. The cells are then viewed with a special light. This test can find some chromosome changes that can’t be seen with standard cytogenetic testing. It’s also a quicker test. […] Polymerase chain reaction (PCR). This is a very sensitive test that can detect very low levels of BCR-ABL in a test sample. It works by increasing the amount of genetic material in a sample so that it can be found. This test can find very small levels of the BCR-ABL gene that other tests may not find. […] Getting your test results Your healthcare provider will contact you with the results. Your provider will talk with you about other tests you may need if CML is found. Make sure you understand the results and what follow-up you need.

• #35 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Conventional bone marrow cytogenetics, specifically chromosome banding analysis (karyotyping) of at least 20 Giemsa-stained metaphases from the bone marrow, is recommended at diagnosis. Karyotyping is used for the detection of the Ph chromosome and can identify atypical (i.e., three way) translocations resulting in Ph chromosome formation. […] RT-PCR testing should be performed along with chromosomal karyotyping at initial diagnosis for baseline BCR-ABL1 transcript identification and quantification. A quantitative RT-PCR test for the relevant BCR-ABL1 transcript should be performed at the initial workup and for therapeutic response assessment and monitoring. […] FISH testing may be used if chromosome banding analysis cannot be performed or if the breakpoint is cryptic and cannot be detected by chromosome banding analysis. FISH tests can detect nearly all variant and cryptic Ph translocations and can confirm the diagnosis of CML if BCR and ABL1 probes are used.

• #36 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Fluorescence In Situ Hybridization (FISH). This laboratory test is used to examine genes and chromosomes in cells. It is a slightly more sensitive method for detecting CML than the standard cytogenetic tests used to identify the Ph chromosome. FISH tests can identify the presence of the BCR::ABL1 gene. […] […] Quantitative Polymerase Chain Reaction (qPCR). The qPCR test is the most sensitive test used to detect and measure the quantity of the BCR::ABL1 gene in blood or bone marrow samples. It can detect very small amounts of the BCR::ABL1 gene, even when the Ph chromosome cannot be detected in blood or bone marrow cells with cytogenetic testing. It is capable of detecting one CML cell among 100,000 normal cells.

• #37 Chronic Myeloid Leukemia (CML) | Diagnosing CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia/diagnosis

  Fluorescence In Situ Hybridization (FISH). This laboratory test is used to examine genes and chromosomes in cells. It is a slightly more sensitive method for detecting CML than the standard cytogenetic tests used to identify the Ph chromosome. FISH tests can identify the presence of the BCR::ABL1 gene. […] […] Quantitative Polymerase Chain Reaction (qPCR). The qPCR test is the most sensitive test used to detect and measure the quantity of the BCR::ABL1 gene in blood or bone marrow samples. It can detect very small amounts of the BCR::ABL1 gene, even when the Ph chromosome cannot be detected in blood or bone marrow cells with cytogenetic testing. It is capable of detecting one CML cell among 100,000 normal cells.

• #38 Chronic Myeloid Leukemia (CML): Diagnosis 

  https://healthlibrary.somc.org/Library/DiseasesConditions/Adult/Cardiovascular/34,BCMLD2

  Cytogenetics. For these tests, cells are grown in a lab for a week or more. The chromosomes inside the cells are then stained with special dyes and looked at with a microscope. Major problems in the chromosomes can often be seen. But smaller changes may not be visible. These tests often take a few weeks because the cells need time to be grown in the lab. […] Fluorescence in situ hybridization (FISH). This test is another way to look for changes in chromosomes. The cells in the sample are stained with fluorescent dyes that will attach only to certain parts of chromosomes. The cells are then viewed with a special light. This test can find some chromosome changes that can’t be seen with standard cytogenetic testing. It’s also a quicker test. […] Polymerase chain reaction (PCR). This is a very sensitive test that can detect very low levels of BCR-ABL in a test sample. It works by increasing the amount of genetic material in a sample so that it can be found. This test can find very small levels of the BCR-ABL gene that other tests may not find. […] Getting your test results Your healthcare provider will contact you with the results. Your provider will talk with you about other tests you may need if CML is found. Make sure you understand the results and what follow-up you need.

• #39 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  PCR can be used to help diagnose CML. […] It’s also useful after treatment to see if copies of the BCR-ABL gene are still there. […] Imaging tests are used to get pictures of the inside of your body. […] They aren’t needed to diagnose CML, but are sometimes used to look for the cause of symptoms or to see if the spleen or liver are enlarged.

• #40 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Conventional bone marrow cytogenetics, specifically chromosome banding analysis (karyotyping) of at least 20 Giemsa-stained metaphases from the bone marrow, is recommended at diagnosis. Karyotyping is used for the detection of the Ph chromosome and can identify atypical (i.e., three way) translocations resulting in Ph chromosome formation. […] RT-PCR testing should be performed along with chromosomal karyotyping at initial diagnosis for baseline BCR-ABL1 transcript identification and quantification. A quantitative RT-PCR test for the relevant BCR-ABL1 transcript should be performed at the initial workup and for therapeutic response assessment and monitoring. […] FISH testing may be used if chromosome banding analysis cannot be performed or if the breakpoint is cryptic and cannot be detected by chromosome banding analysis. FISH tests can detect nearly all variant and cryptic Ph translocations and can confirm the diagnosis of CML if BCR and ABL1 probes are used.

• #41 European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia | Leukemia

  https://www.nature.com/articles/s41375-023-02048-y

  At presentation, up to 85-90% of CML cases have a t(9;22)(q34;q11) on cytogenetic analysis and thus have a standard Ph chromosome, sometimes described as 22q- or der22. […] A minimum of 20 metaphases should be analysed (ideally 25) to ensure detection of ACAs. […] Cytogenetic testing should include a screen for ACAs at diagnosis. […] BCR::ABL1 mRNA transcript type should be determined for all cases prior to treatment to enable appropriate follow up. […] The possibility of a rare BCR::ABL1 variant should be excluded. If testing for rare variants is not available, the diagnostic report should clearly state that the presence of a BCR::ABL1 remains a possibility and that further testing in an appropriate reference laboratory should be performed. […] Identification of atypical BCR::ABL1 variants may be challenging, and there are no CE-marked or Food and Drug Administration (FDA)-approved kits or systems that can detect most rare isoforms. […] For centres that use cytogenetics and/or FISH as the primary screen, the BCR::ABL1 transcript type in positive cases should be determined prior to starting treatment to facilitate accurate assessment of measurable residual disease (MRD) on therapy.

• #42 Tests for Chronic Myeloid Leukemia | American Cancer Society

  https://www.cancer.org/cancer/types/chronic-myeloid-leukemia/detection-diagnosis-staging/how-diagnosed.html

  PCR can be used to help diagnose CML. […] It’s also useful after treatment to see if copies of the BCR-ABL gene are still there. […] Imaging tests are used to get pictures of the inside of your body. […] They aren’t needed to diagnose CML, but are sometimes used to look for the cause of symptoms or to see if the spleen or liver are enlarged.

• #43 Tests for chronic myeloid leukaemia (CML) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/chronic-myeloid-leukaemia-cml/getting-diagnosed/tests-cml

  You usually have a number of tests to check for chronic myeloid leukaemia (CML). Your doctor may suspect or sometimes diagnose leukaemia from a blood test. You then might have more tests to confirm your diagnosis and find out more about the type of leukaemia you have. […] CML tends to develop slowly, so most people dont have any symptoms. People are often diagnosed after having a routine blood test for something else. […] Depending on your symptoms and the results of your blood tests, your GP might arrange for you to go to the hospital. Sometimes this is quite quick, and you might have to go there straight away. This can happen if your GP suspects that you have leukaemia. […] Your specialist usually repeats the blood tests done by your GP. You also have more tests such as: tests on blood sample cells. This is also called immunophenotyping, a bone marrow test, tests to look for changes in the genes and chromosomes of your leukaemia cells, scans such as an x-ray and an ultrasound scan, tests to look at substances on the surface of cells and tissues. These are called tissue typing tests.

• #44 Tests for chronic myeloid leukaemia (CML) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/chronic-myeloid-leukaemia-cml/getting-diagnosed/tests-cml

  You usually have a number of tests to check for chronic myeloid leukaemia (CML). Your doctor may suspect or sometimes diagnose leukaemia from a blood test. You then might have more tests to confirm your diagnosis and find out more about the type of leukaemia you have. […] CML tends to develop slowly, so most people dont have any symptoms. People are often diagnosed after having a routine blood test for something else. […] Depending on your symptoms and the results of your blood tests, your GP might arrange for you to go to the hospital. Sometimes this is quite quick, and you might have to go there straight away. This can happen if your GP suspects that you have leukaemia. […] Your specialist usually repeats the blood tests done by your GP. You also have more tests such as: tests on blood sample cells. This is also called immunophenotyping, a bone marrow test, tests to look for changes in the genes and chromosomes of your leukaemia cells, scans such as an x-ray and an ultrasound scan, tests to look at substances on the surface of cells and tissues. These are called tissue typing tests.

• #45 Chronic Myeloid Leukemia Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq

  CML is identified by too many myeloblasts in the blood and bone marrow, and the disease worsens as the number of myeloblasts increase. […] CML is a clonal disorder that is easily diagnosed because the leukemic cells of more than 95% of patients have a distinctive cytogenetic abnormality, the Philadelphia chromosome (Ph). […] The Ph chromosome results from a reciprocal translocation between the long arms of chromosomes 9 and 22, and it is demonstrable in all hematopoietic precursors. […] Using peripheral blood, molecular techniques can detect the presence of the 9;22 translocation. […] In addition to a health history and physical examination, the initial workup may include: Complete blood count with differential, Blood chemistry studies, Bone marrow aspiration and biopsy, Cytogenetic analysis, Fluorescence in situ hybridization (FISH), Reverse transcriptionpolymerase chain reaction (RT-PCR), CT scan.

• #46 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422

  Bone marrow tests. Bone marrow biopsy and bone marrow aspiration are used to collect bone marrow samples for testing. Bone marrow has a solid and a liquid part. In a bone marrow biopsy, a needle is used to collect a small amount of the solid tissue. In a bone marrow aspiration, a needle is used to draw a sample of the fluid. The samples are typically taken from the hip bone. The samples go to a lab for testing. […] Tests to look for the Philadelphia chromosome. Specialized tests are used to analyze blood or bone marrow samples for the presence of the Philadelphia chromosome or the BCR-ABL gene. These tests may include fluorescence in situ hybridization analysis, also called FISH, and polymerase chain reaction test, also called PCR. […] The phase of chronic myelogenous leukemia refers to the aggressiveness of the disease. Your health care provider determines the phase by measuring the ratio of diseased cells to healthy cells in your blood or bone marrow. A higher ratio of diseased cells means chronic myelogenous leukemia is at a more advanced stage.

• #47 Chronic myeloid leukaemia (CML) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/

  Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes. These cells (sometimes called blasts or leukaemic blasts) gradually crowd the bone marrow, interfering with normal blood cell production. They also spill out of the bone marrow and circulate around the body in the bloodstream. Because they are not fully mature, they are unable to work properly to fight infections. Over time, a shortage of red cells and platelets can cause anaemia, bleeding and/or bruising. […] Most people (more than 90%) are diagnosed in the early chronic phase of CML. Blood counts remain relatively stable and the proportion of blast cells in the bone marrow and blood is low (five per cent or less). Most people are generally well at this stage and have few, if any, troubling symptoms of their disease.

• #48 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Chronic-Myelogenous-Leukemia-Diagnosis.aspx

  For example, 90% of people with chronic myeloid leukaemia have the Philadelphia chromosome. […] Once the diagnosis of a cancer is confirmed, it is staged into stages of the disease progression. […] For CML there are phases of development of the disease. CML is divided into 3 groups that help predict outcome of the cancer. […] In this phase there are less than 10% blast cells in blood. […] In this phase there are more than 10% and less than 20% blast cells in blood or bone marrow. […] In this phase there are over 20% blast cells in blood or bone marrow.

• #49 Chronic myeloid leukaemia (CML) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/

  Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes. These cells (sometimes called blasts or leukaemic blasts) gradually crowd the bone marrow, interfering with normal blood cell production. They also spill out of the bone marrow and circulate around the body in the bloodstream. Because they are not fully mature, they are unable to work properly to fight infections. Over time, a shortage of red cells and platelets can cause anaemia, bleeding and/or bruising. […] Most people (more than 90%) are diagnosed in the early chronic phase of CML. Blood counts remain relatively stable and the proportion of blast cells in the bone marrow and blood is low (five per cent or less). Most people are generally well at this stage and have few, if any, troubling symptoms of their disease.

• #50 Chronic myeloid leukaemia (CML) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/

  Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes. These cells (sometimes called blasts or leukaemic blasts) gradually crowd the bone marrow, interfering with normal blood cell production. They also spill out of the bone marrow and circulate around the body in the bloodstream. Because they are not fully mature, they are unable to work properly to fight infections. Over time, a shortage of red cells and platelets can cause anaemia, bleeding and/or bruising. […] Most people (more than 90%) are diagnosed in the early chronic phase of CML. Blood counts remain relatively stable and the proportion of blast cells in the bone marrow and blood is low (five per cent or less). Most people are generally well at this stage and have few, if any, troubling symptoms of their disease.

• #51 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #52 Chronic myeloid leukaemia (CML) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/leukaemia/chronic-myeloid-leukaemia/

  In about 5% of patients, CML progresses from a relatively stable disease into a more rapidly progressing one. This is known as the accelerated phase of CML. During this time a proportion of blast cells may start to increase in your bone marrow and circulating blood. […] Overall for patients with CML, there is generally a less than 5% risk it will transform into a rapidly progressing disease resembling acute leukaemia. This risk is less than 1% in those who have an excellent response to current drug therapy. […] Each year in Australia around 330 people are diagnosed with CML. Overall, CML is a rare disease, accounting for around 0.03% of all cancers diagnosed. […] CML can occur at any age but it is more common in adults over the age of 40, who account for nearly 70% of all cases. CML occurs more frequently in men than women and is rarely diagnosed in children.

• #53 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Chronic-Myelogenous-Leukemia-Diagnosis.aspx

  For example, 90% of people with chronic myeloid leukaemia have the Philadelphia chromosome. […] Once the diagnosis of a cancer is confirmed, it is staged into stages of the disease progression. […] For CML there are phases of development of the disease. CML is divided into 3 groups that help predict outcome of the cancer. […] In this phase there are less than 10% blast cells in blood. […] In this phase there are more than 10% and less than 20% blast cells in blood or bone marrow. […] In this phase there are over 20% blast cells in blood or bone marrow.

• #54 Chronic myeloid leukaemia (CML) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/leukaemia/chronic-myeloid-leukaemia-cml

  Chronic myeloid leukaemia (CML) is a cancer of the blood cells. […] About 750 people in the UK are diagnosed with CML each year. […] CML usually develops slowly. […] If your GP thinks you may have CML, they will refer you to a haematologist for further tests. […] Tests for CML may include: Blood tests, Bone marrow test, Cytogenetic and molecular tests, Ultrasound scan. […] If there are leukaemia cells in your blood, the haematologist will arrange more tests for you. […] Most people are diagnosed when CML is in the chronic phase. […] In the chronic phase, less than 15 in 100 blood cells in the blood or bone marrow (15%) are blast cells. […] In the accelerated phase, less than 2 in 10 blood cells in the blood or bone marrow (10 to 19%) are blast cells. […] In the blast phase, more than 2 in 10 blood cells in the blood or bone marrow (20%) are blast cells.

• #55 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #56 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #57 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #58 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #59 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Chronic-Myelogenous-Leukemia-Diagnosis.aspx

  For example, 90% of people with chronic myeloid leukaemia have the Philadelphia chromosome. […] Once the diagnosis of a cancer is confirmed, it is staged into stages of the disease progression. […] For CML there are phases of development of the disease. CML is divided into 3 groups that help predict outcome of the cancer. […] In this phase there are less than 10% blast cells in blood. […] In this phase there are more than 10% and less than 20% blast cells in blood or bone marrow. […] In this phase there are over 20% blast cells in blood or bone marrow.

• #60 Chronic myelogenous leukemia – Wikipedia

  https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia

  The patient is considered to be in the accelerated phase if any of the above are present. The accelerated phase is significant because it signals that the disease is progressing and transformation to blast crisis is imminent. […] Blast crisis is diagnosed if any of the following are present in a patient with CML: 20% blasts in the blood or bone marrow.

• #61 Pathology Outlines – Chronic myeloid leukemia (CML), BCR::ABL1 positive

  https://www.pathologyoutlines.com/topic/myeloproliferativecml.html

  Blast phase (BP): ≥ 20% blasts in marrow or blood or the presence of an extramedullary proliferation of blasts. […] Chronic phase: Leukocytosis with predominantly neutrophils and myelocytes, basophilia and eosinophilia, t(9;22)(q34;q11.2) by FISH, conventional cytogenetics or PCR. […] Most important prognostic indicator is response to tyrosine kinase inhibitors at the hematological, cytogenetic and molecular level. […] Chronic phase: tyrosine kinase inhibitor (TKI), acting by competitive inhibition at the ATP binding site of BCR-ABL1 oncoprotein. […] Chronic myeloid leukemia resistant to imatinib can be treated by second generation tyrosine kinase inhibitor agents such as nilotinib, dasatinib and bosutinib. […] 90 – 95% of chronic myeloid leukemia is characterized by t(9;22)(q34.1;q11.2) reciprocal translocation that results in the Ph chromosome. […] Translocation fuses the BCR gene on chromosome 22 with regions of ABL1 on chromosome 9 and generates the BCR-ABL1 fusion gene that characterizes leukemic cells.

• #62 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #63 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #64 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #65 CML – Diagnosis | Sarah Cannon

  https://sarahcannon.com/for-patients/learn-about-cancer/blood-cancer/cml/diagnosis.dot

  Most patients are diagnosed during CML’s chronic phase when symptoms are mild or not noticeable. During this phase, your white cells can still fight infection and long-term drug therapy is used to control your CML. […] If you’re diagnosed during accelerated phase CML, you may have: A lower-than-normal number of red cells, A lower-than-normal number of platelets, An increase or decrease in white cells, A high number of blast cells in the blood and bone marrow, A swollen spleen, which can cause stomach discomfort, A general feeling of ill health. […] If you’re diagnosed in CML’s blast crisis phase, you usually have an increased number of blast cells in your bone marrow and blood. In addition, blast crisis phase patients also have a lower-than-normal number of red cells and platelets. […] In this phase, it is common to experience infection, bleeding, a lack of energy or feelings of tiredness, shortness of breath, stomach pain or bone pain. […] Once CML reaches this more severe, advanced phase, its effects on patients are similar to those caused by an acute leukemia and can be life-threatening.

• #66 Chronic Myeloid Leukemia (CML) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/chronic-myeloid-leukemia-cml

  Chronic myeloid leukemia (CML) occurs when a pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, leading to a striking overproduction of mature and immature granulocytes. […] Peripheral blood smear, bone marrow aspirate, and demonstration of the Philadelphia chromosome are diagnostic. […] Chronic myeloid leukemia is most frequently suspected based on an abnormal CBC obtained incidentally or during evaluation of splenomegaly. […] Diagnosis is confirmed by finding the Ph chromosome in samples examined with cytogenetic or molecular studies. […] The peripheral smear (typically showing immature granulocytes, basophilia, and eosinophilia) helps distinguish CML from leukocytosis of other etiologies (eg, leukocytosis due to infection). […] Tyrosine kinase inhibitors are extremely effective, prolong survival, and may even be curative. […] Stem cell transplantation can be curative and may help patients who do not respond to tyrosine kinase inhibitors or who progress to accelerated or blast phase.

• #67 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Chronic myeloid leukemia (CML) is a malignancy characterized by the presence of the Philadelphia (Ph) chromosome. A presumptive diagnosis of CML is usually made by examining blood cell counts and peripheral smears, often during the chronic phase. Detection of BCR-ABL1 in the blood or bone marrow confirms the diagnosis. Laboratory methods used in the diagnosis, prognosis, and monitoring of CML include chromosome banding analysis (karyotyping), fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcription polymerase chain reaction (RT-PCR). […] The diagnosis of CML is confirmed by the presence of the Ph chromosome and/or BCR-ABL1 transcripts in blood or bone marrow by chromosome banding analysis, RT-PCR, or FISH. If neither the Ph chromosome nor BCR-ABL1 are detected, evaluation for other myeloproliferative neoplasms should be considered.

• #68 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422

  Bone marrow tests. Bone marrow biopsy and bone marrow aspiration are used to collect bone marrow samples for testing. Bone marrow has a solid and a liquid part. In a bone marrow biopsy, a needle is used to collect a small amount of the solid tissue. In a bone marrow aspiration, a needle is used to draw a sample of the fluid. The samples are typically taken from the hip bone. The samples go to a lab for testing. […] Tests to look for the Philadelphia chromosome. Specialized tests are used to analyze blood or bone marrow samples for the presence of the Philadelphia chromosome or the BCR-ABL gene. These tests may include fluorescence in situ hybridization analysis, also called FISH, and polymerase chain reaction test, also called PCR. […] The phase of chronic myelogenous leukemia refers to the aggressiveness of the disease. Your health care provider determines the phase by measuring the ratio of diseased cells to healthy cells in your blood or bone marrow. A higher ratio of diseased cells means chronic myelogenous leukemia is at a more advanced stage.

• #69 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  Conventional bone marrow cytogenetics, specifically chromosome banding analysis (karyotyping) of at least 20 Giemsa-stained metaphases from the bone marrow, is recommended at diagnosis. Karyotyping is used for the detection of the Ph chromosome and can identify atypical (i.e., three way) translocations resulting in Ph chromosome formation. […] RT-PCR testing should be performed along with chromosomal karyotyping at initial diagnosis for baseline BCR-ABL1 transcript identification and quantification. A quantitative RT-PCR test for the relevant BCR-ABL1 transcript should be performed at the initial workup and for therapeutic response assessment and monitoring. […] FISH testing may be used if chromosome banding analysis cannot be performed or if the breakpoint is cryptic and cannot be detected by chromosome banding analysis. FISH tests can detect nearly all variant and cryptic Ph translocations and can confirm the diagnosis of CML if BCR and ABL1 probes are used.

• #70 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  The results from standard hematology tests, cytogenetic tests, and molecular tests are used to assess the respective hematologic, cytogenetic, and molecular responses to tyrosine kinase inhibitor (TKI) therapy, and these test results may have prognostic significance. Laboratory testing is also used for minimal residual disease (MRD) detection and monitoring. […] Mutation analysis of the BCR-ABL1 kinase domain (e.g., by massively parallel sequencing) is recommended in cases of relapse or failure during first-line therapy. If no kinase domain mutations are identified, testing with a myeloid mutation panel may be useful because other mutations (i.e., not BCR-ABL1) may lead to therapeutic resistance.

• #71 Chronic Myelogenous Leukemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK531459/

  Initially, if CML is suspected, cytogenetic testing, fluorescent in situ hybridization, and/or reverse transcriptase-polymerase chain reaction (PCR) to determine the Philadelphia chromosome, or BCR-ABL1 oncoprotein presence can be performed on peripheral blood. At the time of diagnosis, laboratory blood testing should include a complete blood count with differential, chemistry panel, hepatitis panel, and a quantitative PCR for BCR-ABL1. A baseline bone marrow aspirate and biopsy should be performed with cytogenetics. […] If chronic phase CML is established, additional evaluation includes determining the risk score using Sokal et al or Hasford et al risk calculations before determining first-line therapy. […] There are 4 United States Food and Drug Administration (FDA)-approved, first-line treatments for chronic phase CML that are commercially available tyrosine kinase inhibitors, including first-generation imatinib and second-generation dasatinib, nilotinib, and bosutinib. […] For chronic phase, CML with intermediate- or high-risk score, second-generation tyrosine kinase inhibitors (bosutinib, dasatinib, nilotinib) as first-line therapy may have an additional benefit over imatinib.

• #72 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  The results from standard hematology tests, cytogenetic tests, and molecular tests are used to assess the respective hematologic, cytogenetic, and molecular responses to tyrosine kinase inhibitor (TKI) therapy, and these test results may have prognostic significance. Laboratory testing is also used for minimal residual disease (MRD) detection and monitoring. […] Mutation analysis of the BCR-ABL1 kinase domain (e.g., by massively parallel sequencing) is recommended in cases of relapse or failure during first-line therapy. If no kinase domain mutations are identified, testing with a myeloid mutation panel may be useful because other mutations (i.e., not BCR-ABL1) may lead to therapeutic resistance.

• #73 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  The results from standard hematology tests, cytogenetic tests, and molecular tests are used to assess the respective hematologic, cytogenetic, and molecular responses to tyrosine kinase inhibitor (TKI) therapy, and these test results may have prognostic significance. Laboratory testing is also used for minimal residual disease (MRD) detection and monitoring. […] Mutation analysis of the BCR-ABL1 kinase domain (e.g., by massively parallel sequencing) is recommended in cases of relapse or failure during first-line therapy. If no kinase domain mutations are identified, testing with a myeloid mutation panel may be useful because other mutations (i.e., not BCR-ABL1) may lead to therapeutic resistance.

• #74 Chronic Myelogenous Leukemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK531459/

  In the event of tyrosine kinase inhibitor resistance, analysis of the BCR-ABL1 mutational profile may be useful in choosing second or third-line therapy. […] The T315I mutation has been shown to confer resistance to imatinib and all second-generation tyrosine kinase inhibitors. In these patients, ponatinib should be considered.

• #75 Chronic Myeloid Leukemia: Laboratory Evaluation | Test Guide | Quest Diagnostics Chronic Myeloid Leukemia: Laboratory Evaluation Chronic Myeloid Leukemia: Laboratory Evaluation

  https://testdirectory.questdiagnostics.com/test/test-guides/TG_CML/chronic-myeloid-leukemia-laboratory-evaluation

  This Test Guide provides an overview of tests that assist with the diagnosis, classification, prognosis, and management of chronic myeloid leukemia (CML). […] When blood morphology findings suggest CML, the diagnosis is confirmed by identifying Ph using karyotyping and/or by detecting the BCR-ABL1 fusion gene with polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) tests. […] Laboratory tests that evaluate ABL1 kinase domain mutations may help guide treatment change when patients develop primary or secondary resistance to TKI therapy. […] ABL1 kinase domain mutation analysis is also recommended to help select initial treatment for patients with blast-phase CML. […] Table 2 provides an overview of the types of laboratory tests used for diagnosing CML and recognizing CML phases, determining prognosis, and monitoring treatment response.

• #76 Chronic Myeloid Leukemia (CML) | Learn What Is CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia

  Chronic myeloid leukemia (CML) is usually diagnosed in its chronic phase when treatment is very effective for most patients. […] Most CML patients are treated with daily oral drug therapy. […] Since the introduction of tyrosine kinase inhibitor (TKI) therapy in 2001, CML has been transformed from a life-threatening disease to a manageable chronic condition for most patients. People are living longer with CML and experiencing fewer treatment side effects. […] Talk with your doctor about your diagnostic tests and what the results mean. […] Make sure your doctor continually monitors your response to medication, which is essential to bringing your CML under control. […] All cases of CML are caused by the BCR::ABL1 fusion gene. This gene is not found in normal blood cells. […] The BCR::ABL1 gene is formed by a translocation between parts of chromosomes 9 and 22 in a single bone marrow cell during cell division. […] The abnormal chromosome 22 is called the „Philadelphia chromosome” (Ph chromosome).

• #77 Tests before and after diagnosis | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/chronic-myeloid-leukaemia-cml/cml-symptoms-testing/cml-testing/

  Tests to diagnose CML: […] Youll have a series of tests to confirm that you have CML. If you are diagnosed, youll then have some more tests to help your hospital team decide which is the best treatment for you. […] Not everybody will need every test available, but these are some of the tests you may have: […] A bone marrow biopsy is a minor surgical procedure done in hospital as a day patient. […] Every three months, you will need to have a genetic test known as a BCR::ABL1 test. […] During your treatment, your hospital team will run regular tests to monitor the CML and any side effects you experience. […] The tests you have throughout your treatment for CML will measure how well the treatment is working. […] When your blood counts return to normal, youre said to have achieved a complete haematological response (CHR).

• #78 Tests before and after diagnosis | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/chronic-myeloid-leukaemia-cml/cml-symptoms-testing/cml-testing/

  Tests to diagnose CML: […] Youll have a series of tests to confirm that you have CML. If you are diagnosed, youll then have some more tests to help your hospital team decide which is the best treatment for you. […] Not everybody will need every test available, but these are some of the tests you may have: […] A bone marrow biopsy is a minor surgical procedure done in hospital as a day patient. […] Every three months, you will need to have a genetic test known as a BCR::ABL1 test. […] During your treatment, your hospital team will run regular tests to monitor the CML and any side effects you experience. […] The tests you have throughout your treatment for CML will measure how well the treatment is working. […] When your blood counts return to normal, youre said to have achieved a complete haematological response (CHR).

• #79 Chronic Myeloid Leukaemia (Causes, Symptoms and Treatment)

  https://patient.info/doctor/chronic-myeloid-leukaemia-pro

  Goals of treatment are: Haematologic remission (normal FBC count, physical examination, ie no organomegaly), Cytogenetic remission (normal chromosome returns with 0% Ph-positive cells), Molecular remission (negative PCR result for the mutational BCR-ABL m-RNA). […] Drug treatment is superior to allogeneic stem cell transplantation (alloSCT) in first-line therapy of CML, because of transplant-related mortality. […] In recent years, tyrosine kinase inhibitors (TKIs) have come to dominate the treatment of CML. […] Imatinib is now firmly established as an effective therapy for newly diagnosed patients with CML. […] Rates of complete cytogenetic response (CCgR) among patients receiving imatinib were 69% by 12 months and 87% by 60 months. […] For first-line treatment of CML, the National Institute for Health and Care Excellence (NICE) recommends the following: Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia chromosome-positive CML. […] The introduction of TKIs has greatly improved the prognoses for CML patients. […] Individuals diagnosed with chronic phase CML are expected to reach normal or near-normal life expectancy.

• #80 Chronic Myeloid Leukaemia (Causes, Symptoms and Treatment)

  https://patient.info/doctor/chronic-myeloid-leukaemia-pro

  Goals of treatment are: Haematologic remission (normal FBC count, physical examination, ie no organomegaly), Cytogenetic remission (normal chromosome returns with 0% Ph-positive cells), Molecular remission (negative PCR result for the mutational BCR-ABL m-RNA). […] Drug treatment is superior to allogeneic stem cell transplantation (alloSCT) in first-line therapy of CML, because of transplant-related mortality. […] In recent years, tyrosine kinase inhibitors (TKIs) have come to dominate the treatment of CML. […] Imatinib is now firmly established as an effective therapy for newly diagnosed patients with CML. […] Rates of complete cytogenetic response (CCgR) among patients receiving imatinib were 69% by 12 months and 87% by 60 months. […] For first-line treatment of CML, the National Institute for Health and Care Excellence (NICE) recommends the following: Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia chromosome-positive CML. […] The introduction of TKIs has greatly improved the prognoses for CML patients. […] Individuals diagnosed with chronic phase CML are expected to reach normal or near-normal life expectancy.

• #81 Tests before and after diagnosis | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/chronic-myeloid-leukaemia-cml/cml-symptoms-testing/cml-testing/

  This is another way of measuring how youve responded to the treatment youre on. […] The BCR::ABL1 or PCR test is a molecular test and is the best way to monitor levels of leukaemia in the blood. […] If no cancer cells at all can be detected in your PCR tests, you might hear your results referred to as undetectable transcripts. This is also sometimes called a complete molecular response (CMR).

• #82 Chronic myeloid leukemia (CML) | MLL

  https://www.mll.com/en/chronic-myeloid-leukemia-cml/chronic-myeloid-leukemia-cml

  Through the use of tyrosine kinase inhibitors, the life expectancy of patients with chronic myeloid leukemia is almost comparable to a healthy control population. Here you can learn more about the classification, diagnosis and prognosis of CML. Cytomorphology is used for the diagnosis of CML and significantly contributes to the differentiation from other myeloproliferative diseases. Furthermore, it is relevant for the staging of CML. Hematologic remission is assessed by cytomorphologic criteria during follow-up under therapy. Immunophenotyping is not part of the routine diagnostic CML workflow at initial diagnosis or in remission. However, it is important in the case of blast phase (BP) to differentiate myeloid BP from BP of lymphoid origin. The presence of a Philadelphia chromosome or rather a BCR::ABL1 rearrangement defines chronic myeloid leukemia. In 90% of CML patients, a Philadelphia chromosome is present, which results from the reciprocal translocation between the long arm of a chromosome 9 and the long arm of a chromosome 22 (t(9;22)(q34;q11)). The presence of additional chromosomal aberrations besides t(9;22) at initial diagnosis or during the disease course can impact the prognosis. Testing for additional aberrations is indicated at initial diagnosis, treatment failure/resistance, and (suspected) progression. FISH analysis can confirm or exclude the presence of a BCR::ABL1 rearrangement within 24 hours. Molecular genetics with the methods of PCR and sequencing plays the central role in CML diagnostics. In addition to diagnosis (detection of the BCR::ABL1 fusion gene and determination of the transcript type), these diagnostic methods are now routinely used both to monitor therapy response and to identify resistance mutations in case of therapy failure. The key method for quantifying treatment response is the highly sensitive (10-5) real-time PCR. BCR::ABL1 expression is quantified relative to a reference gene (usually ABL1). The molecular response criteria are crucial for therapy planning, which today also includes the possibility of therapy-free remission. Sensitive molecular genetic monitoring is essential, both to assess eligibility for TKI discontinuation and to detect molecular relapses at an early stage. Under TKI treatment, there is a risk of TKI resistance in case BCR::ABL1 expression increases again. In this situation, sequencing for BCR::ABL1 mutations should be performed. „High-risk” additional abnormalities are predictive for a reduced response to therapy as well as for an increased risk of progression. Accordingly, they are relevant for therapy planning. Achieving a major molecular response (MMR, BCR::ABL1 0.1%) is predictive of a CML-specific survival rate approaching 100%. In addition, it is considered established that the achievement of a deep molecular remission (BCR::ABL1 0.01%) is associated with a reduced risk of loss of treatment response as well as the occurrence of TKI resistance. The EUTOS long term survival (ELTS) score described in 2016 holds the most prognostic relevance in the current era of tyrosine kinase inhibitors and should therefore be used for risk stratification according to the ELN recommendation.

• #83 Chronic Myeloid Leukemia: Evaluation and Diagnosis | MDedge

  https://ma1.mdedge.com/content/chronic-myeloid-leukemia-evaluation-and-diagnosis

  The most sensitive method for detecting BCR-ABL1 mRNA transcripts is the quantitative real-time PCR (RQ-PCR) assay, which is typically done on peripheral blood. […] This test should be done during the initial diagnostic workup in order to confirm the presence of BCR-ABL1 transcripts, and it is used as a standard method for monitoring response to TKI therapy. […] The NCCN and the ELN recommend monitoring RQ-PCR from the peripheral blood every 3 months in order to assess response to TKIs. […] Given the successful treatments available for patients with CML, it is crucial to identify patients with this disease, ensure they receive a complete, appropriate diagnostic workup including a bone marrow biopsy and aspiration with cytogenetic testing, and select the best therapy for each individual patient.

• #84 Chronic myeloid leukaemia (CML) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/leukaemia/chronic-myeloid-leukaemia-cml

  The aim of treatment is to put CML into remission (where there are no signs of leukaemia cells). […] The main treatment for CML is with drugs called tyrosine kinase inhibitors (TKIs). […] If CML is not controlled by TKIs or if you are diagnosed in the blast phase, your doctors may suggest chemotherapy and a stem cell transplant. […] If you have treatment with a TKI, you will be monitored by your healthcare team every 1 to 2 weeks. […] These test results help your doctors know how well the treatment is working to control the leukaemia.

• #85 Chronic myeloid leukemia (CML) | MLL

  https://www.mll.com/en/chronic-myeloid-leukemia-cml/chronic-myeloid-leukemia-cml

  Through the use of tyrosine kinase inhibitors, the life expectancy of patients with chronic myeloid leukemia is almost comparable to a healthy control population. Here you can learn more about the classification, diagnosis and prognosis of CML. Cytomorphology is used for the diagnosis of CML and significantly contributes to the differentiation from other myeloproliferative diseases. Furthermore, it is relevant for the staging of CML. Hematologic remission is assessed by cytomorphologic criteria during follow-up under therapy. Immunophenotyping is not part of the routine diagnostic CML workflow at initial diagnosis or in remission. However, it is important in the case of blast phase (BP) to differentiate myeloid BP from BP of lymphoid origin. The presence of a Philadelphia chromosome or rather a BCR::ABL1 rearrangement defines chronic myeloid leukemia. In 90% of CML patients, a Philadelphia chromosome is present, which results from the reciprocal translocation between the long arm of a chromosome 9 and the long arm of a chromosome 22 (t(9;22)(q34;q11)). The presence of additional chromosomal aberrations besides t(9;22) at initial diagnosis or during the disease course can impact the prognosis. Testing for additional aberrations is indicated at initial diagnosis, treatment failure/resistance, and (suspected) progression. FISH analysis can confirm or exclude the presence of a BCR::ABL1 rearrangement within 24 hours. Molecular genetics with the methods of PCR and sequencing plays the central role in CML diagnostics. In addition to diagnosis (detection of the BCR::ABL1 fusion gene and determination of the transcript type), these diagnostic methods are now routinely used both to monitor therapy response and to identify resistance mutations in case of therapy failure. The key method for quantifying treatment response is the highly sensitive (10-5) real-time PCR. BCR::ABL1 expression is quantified relative to a reference gene (usually ABL1). The molecular response criteria are crucial for therapy planning, which today also includes the possibility of therapy-free remission. Sensitive molecular genetic monitoring is essential, both to assess eligibility for TKI discontinuation and to detect molecular relapses at an early stage. Under TKI treatment, there is a risk of TKI resistance in case BCR::ABL1 expression increases again. In this situation, sequencing for BCR::ABL1 mutations should be performed. „High-risk” additional abnormalities are predictive for a reduced response to therapy as well as for an increased risk of progression. Accordingly, they are relevant for therapy planning. Achieving a major molecular response (MMR, BCR::ABL1 0.1%) is predictive of a CML-specific survival rate approaching 100%. In addition, it is considered established that the achievement of a deep molecular remission (BCR::ABL1 0.01%) is associated with a reduced risk of loss of treatment response as well as the occurrence of TKI resistance. The EUTOS long term survival (ELTS) score described in 2016 holds the most prognostic relevance in the current era of tyrosine kinase inhibitors and should therefore be used for risk stratification according to the ELN recommendation.

• #86 Chronic myeloid leukemia (CML) | MLL

  https://www.mll.com/en/chronic-myeloid-leukemia-cml/chronic-myeloid-leukemia-cml

  Through the use of tyrosine kinase inhibitors, the life expectancy of patients with chronic myeloid leukemia is almost comparable to a healthy control population. Here you can learn more about the classification, diagnosis and prognosis of CML. Cytomorphology is used for the diagnosis of CML and significantly contributes to the differentiation from other myeloproliferative diseases. Furthermore, it is relevant for the staging of CML. Hematologic remission is assessed by cytomorphologic criteria during follow-up under therapy. Immunophenotyping is not part of the routine diagnostic CML workflow at initial diagnosis or in remission. However, it is important in the case of blast phase (BP) to differentiate myeloid BP from BP of lymphoid origin. The presence of a Philadelphia chromosome or rather a BCR::ABL1 rearrangement defines chronic myeloid leukemia. In 90% of CML patients, a Philadelphia chromosome is present, which results from the reciprocal translocation between the long arm of a chromosome 9 and the long arm of a chromosome 22 (t(9;22)(q34;q11)). The presence of additional chromosomal aberrations besides t(9;22) at initial diagnosis or during the disease course can impact the prognosis. Testing for additional aberrations is indicated at initial diagnosis, treatment failure/resistance, and (suspected) progression. FISH analysis can confirm or exclude the presence of a BCR::ABL1 rearrangement within 24 hours. Molecular genetics with the methods of PCR and sequencing plays the central role in CML diagnostics. In addition to diagnosis (detection of the BCR::ABL1 fusion gene and determination of the transcript type), these diagnostic methods are now routinely used both to monitor therapy response and to identify resistance mutations in case of therapy failure. The key method for quantifying treatment response is the highly sensitive (10-5) real-time PCR. BCR::ABL1 expression is quantified relative to a reference gene (usually ABL1). The molecular response criteria are crucial for therapy planning, which today also includes the possibility of therapy-free remission. Sensitive molecular genetic monitoring is essential, both to assess eligibility for TKI discontinuation and to detect molecular relapses at an early stage. Under TKI treatment, there is a risk of TKI resistance in case BCR::ABL1 expression increases again. In this situation, sequencing for BCR::ABL1 mutations should be performed. „High-risk” additional abnormalities are predictive for a reduced response to therapy as well as for an increased risk of progression. Accordingly, they are relevant for therapy planning. Achieving a major molecular response (MMR, BCR::ABL1 0.1%) is predictive of a CML-specific survival rate approaching 100%. In addition, it is considered established that the achievement of a deep molecular remission (BCR::ABL1 0.01%) is associated with a reduced risk of loss of treatment response as well as the occurrence of TKI resistance. The EUTOS long term survival (ELTS) score described in 2016 holds the most prognostic relevance in the current era of tyrosine kinase inhibitors and should therefore be used for risk stratification according to the ELN recommendation.

• #87 Chronic Myeloid Leukemia: Evaluation and Diagnosis | MDedge

  https://ma1.mdedge.com/content/chronic-myeloid-leukemia-evaluation-and-diagnosis

  The most sensitive method for detecting BCR-ABL1 mRNA transcripts is the quantitative real-time PCR (RQ-PCR) assay, which is typically done on peripheral blood. […] This test should be done during the initial diagnostic workup in order to confirm the presence of BCR-ABL1 transcripts, and it is used as a standard method for monitoring response to TKI therapy. […] The NCCN and the ELN recommend monitoring RQ-PCR from the peripheral blood every 3 months in order to assess response to TKIs. […] Given the successful treatments available for patients with CML, it is crucial to identify patients with this disease, ensure they receive a complete, appropriate diagnostic workup including a bone marrow biopsy and aspiration with cytogenetic testing, and select the best therapy for each individual patient.

• #88 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  The results from standard hematology tests, cytogenetic tests, and molecular tests are used to assess the respective hematologic, cytogenetic, and molecular responses to tyrosine kinase inhibitor (TKI) therapy, and these test results may have prognostic significance. Laboratory testing is also used for minimal residual disease (MRD) detection and monitoring. […] Mutation analysis of the BCR-ABL1 kinase domain (e.g., by massively parallel sequencing) is recommended in cases of relapse or failure during first-line therapy. If no kinase domain mutations are identified, testing with a myeloid mutation panel may be useful because other mutations (i.e., not BCR-ABL1) may lead to therapeutic resistance.

• #89 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  The results from standard hematology tests, cytogenetic tests, and molecular tests are used to assess the respective hematologic, cytogenetic, and molecular responses to tyrosine kinase inhibitor (TKI) therapy, and these test results may have prognostic significance. Laboratory testing is also used for minimal residual disease (MRD) detection and monitoring. […] Mutation analysis of the BCR-ABL1 kinase domain (e.g., by massively parallel sequencing) is recommended in cases of relapse or failure during first-line therapy. If no kinase domain mutations are identified, testing with a myeloid mutation panel may be useful because other mutations (i.e., not BCR-ABL1) may lead to therapeutic resistance.

• #90 Chronic myeloid leukemia (CML) | MLL

  https://www.mll.com/en/chronic-myeloid-leukemia-cml/chronic-myeloid-leukemia-cml

  Through the use of tyrosine kinase inhibitors, the life expectancy of patients with chronic myeloid leukemia is almost comparable to a healthy control population. Here you can learn more about the classification, diagnosis and prognosis of CML. Cytomorphology is used for the diagnosis of CML and significantly contributes to the differentiation from other myeloproliferative diseases. Furthermore, it is relevant for the staging of CML. Hematologic remission is assessed by cytomorphologic criteria during follow-up under therapy. Immunophenotyping is not part of the routine diagnostic CML workflow at initial diagnosis or in remission. However, it is important in the case of blast phase (BP) to differentiate myeloid BP from BP of lymphoid origin. The presence of a Philadelphia chromosome or rather a BCR::ABL1 rearrangement defines chronic myeloid leukemia. In 90% of CML patients, a Philadelphia chromosome is present, which results from the reciprocal translocation between the long arm of a chromosome 9 and the long arm of a chromosome 22 (t(9;22)(q34;q11)). The presence of additional chromosomal aberrations besides t(9;22) at initial diagnosis or during the disease course can impact the prognosis. Testing for additional aberrations is indicated at initial diagnosis, treatment failure/resistance, and (suspected) progression. FISH analysis can confirm or exclude the presence of a BCR::ABL1 rearrangement within 24 hours. Molecular genetics with the methods of PCR and sequencing plays the central role in CML diagnostics. In addition to diagnosis (detection of the BCR::ABL1 fusion gene and determination of the transcript type), these diagnostic methods are now routinely used both to monitor therapy response and to identify resistance mutations in case of therapy failure. The key method for quantifying treatment response is the highly sensitive (10-5) real-time PCR. BCR::ABL1 expression is quantified relative to a reference gene (usually ABL1). The molecular response criteria are crucial for therapy planning, which today also includes the possibility of therapy-free remission. Sensitive molecular genetic monitoring is essential, both to assess eligibility for TKI discontinuation and to detect molecular relapses at an early stage. Under TKI treatment, there is a risk of TKI resistance in case BCR::ABL1 expression increases again. In this situation, sequencing for BCR::ABL1 mutations should be performed. „High-risk” additional abnormalities are predictive for a reduced response to therapy as well as for an increased risk of progression. Accordingly, they are relevant for therapy planning. Achieving a major molecular response (MMR, BCR::ABL1 0.1%) is predictive of a CML-specific survival rate approaching 100%. In addition, it is considered established that the achievement of a deep molecular remission (BCR::ABL1 0.01%) is associated with a reduced risk of loss of treatment response as well as the occurrence of TKI resistance. The EUTOS long term survival (ELTS) score described in 2016 holds the most prognostic relevance in the current era of tyrosine kinase inhibitors and should therefore be used for risk stratification according to the ELN recommendation.

• #91 Chronic Myeloid Leukemia – CML | Choose the Right Test

  https://arupconsult.com/content/chronic-myelogenous-leukemia

  The results from standard hematology tests, cytogenetic tests, and molecular tests are used to assess the respective hematologic, cytogenetic, and molecular responses to tyrosine kinase inhibitor (TKI) therapy, and these test results may have prognostic significance. Laboratory testing is also used for minimal residual disease (MRD) detection and monitoring. […] Mutation analysis of the BCR-ABL1 kinase domain (e.g., by massively parallel sequencing) is recommended in cases of relapse or failure during first-line therapy. If no kinase domain mutations are identified, testing with a myeloid mutation panel may be useful because other mutations (i.e., not BCR-ABL1) may lead to therapeutic resistance.

• #92 Chronic Myelogenous Leukemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK531459/

  In the event of tyrosine kinase inhibitor resistance, analysis of the BCR-ABL1 mutational profile may be useful in choosing second or third-line therapy. […] The T315I mutation has been shown to confer resistance to imatinib and all second-generation tyrosine kinase inhibitors. In these patients, ponatinib should be considered.

• #93 Chronic Myelogenous Leukemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK531459/

  In the event of tyrosine kinase inhibitor resistance, analysis of the BCR-ABL1 mutational profile may be useful in choosing second or third-line therapy. […] The T315I mutation has been shown to confer resistance to imatinib and all second-generation tyrosine kinase inhibitors. In these patients, ponatinib should be considered.

• #94 Diagnosing Chronic Myelogenous Leukemia | NYU Langone Health

  https://nyulangone.org/conditions/chronic-myelogenous-leukemia/diagnosis

  Diagnosing Chronic Myelogenous Leukemia […] Specialists at NYU Langone are experienced at identifying all types of leukemia. […] Chronic myelogenous leukemia, commonly known as CML, is a slow-growing cancer in which the bone marrow produces too many immature white blood cells. […] Doctors may suspect you have CML if routine blood tests reveal elevated levels of both mature and immature white cells in the blood. Symptoms include fatigue, fever, and night sweats. […] The different types of leukemia are treated differently, so it’s important to obtain the correct diagnosis. […] During an initial exam, your oncologist draws blood to check the numbers of white cells, red cells, and platelets in it. […] This blood test provides information about the number, type, and shape of blood cells.

• #95 CML Patients Deserve Better Answers

  https://asuragen.com/cmlanswers/

  CML is usually suspected based on routine blood work, which is one reason why its important to have an annual checkup. […] If CML is suspected on routine bloodwork, it will need to be confirmed with multiple tests requiring blood and bone marrow samples. An important part of the diagnosis is identifying the presence of the Philadelphia chromosome, which everyone with CML has. […] Once CML is confirmed, its extremely important to get treatment and monitoringeven if you dont feel sick. The excess growth of cancer cells eventually crowds out healthy cells, which can lead to severe sickness and death. […] Monitoring is critical since its a key part of how most CML cases were transformed from life-threatening to manageable. The purpose of monitoring is to determine how well the medication is doing its job.

• #96 Chronic Myeloid Leukemia: Evaluation and Diagnosis | MDedge

  https://ma1.mdedge.com/content/chronic-myeloid-leukemia-evaluation-and-diagnosis

  The most sensitive method for detecting BCR-ABL1 mRNA transcripts is the quantitative real-time PCR (RQ-PCR) assay, which is typically done on peripheral blood. […] This test should be done during the initial diagnostic workup in order to confirm the presence of BCR-ABL1 transcripts, and it is used as a standard method for monitoring response to TKI therapy. […] The NCCN and the ELN recommend monitoring RQ-PCR from the peripheral blood every 3 months in order to assess response to TKIs. […] Given the successful treatments available for patients with CML, it is crucial to identify patients with this disease, ensure they receive a complete, appropriate diagnostic workup including a bone marrow biopsy and aspiration with cytogenetic testing, and select the best therapy for each individual patient.

• #97 Chronic Myeloid Leukemia (CML) | Learn What Is CML | LLS

  https://www.lls.org/leukemia/chronic-myeloid-leukemia

  Chronic myeloid leukemia (CML) is usually diagnosed in its chronic phase when treatment is very effective for most patients. […] Most CML patients are treated with daily oral drug therapy. […] Since the introduction of tyrosine kinase inhibitor (TKI) therapy in 2001, CML has been transformed from a life-threatening disease to a manageable chronic condition for most patients. People are living longer with CML and experiencing fewer treatment side effects. […] Talk with your doctor about your diagnostic tests and what the results mean. […] Make sure your doctor continually monitors your response to medication, which is essential to bringing your CML under control. […] All cases of CML are caused by the BCR::ABL1 fusion gene. This gene is not found in normal blood cells. […] The BCR::ABL1 gene is formed by a translocation between parts of chromosomes 9 and 22 in a single bone marrow cell during cell division. […] The abnormal chromosome 22 is called the „Philadelphia chromosome” (Ph chromosome).

Zobacz więcej